Why the NIH is studying a New Jersey lab's COVID-19 treatment

We've been keeping tabs on a New Jersey lab called BioAegis because of their work with the protein Gelsolin, which they say has potential to be an effective therapy for very ill COVID-19 patients. When we found out that Dr. John Gallin, Chief Scientific Officer of the NIH Clinical Center and the NIH Associate Director for Clinical Research was also studying the protein, we asked him to join KYW In Depth to talk about what he thinks the possibilities are and why he wanted to take a closer look. We're also joined by Dr. Susan Levinson, co-founder and CEO of BioAegis Therapeutics to break down where their treatment stands in the regulatory approval process and how they see Gelsolin being used if it's approved by the FDA. More information about the NIH Clinical Center: https://clinicalcenter.nih.gov/ And about BioAegis: https://www.bioaegistherapeutics.com/ See omnystudio.com/policies/listener for privacy information.

To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy

Learn more about your ad choices. Visit https://podcastchoices.com/adchoices